Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Featured Resources STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months Case study
These are found in about 0.005% of the population
Retatrutide is in Phase 3 trials for type 2 diabetes (TRANSCEND-T2D program), obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease in patients with type 2 diabetes, knee osteoarthritis, and cardiovascular outcomes [1][8][10][11]
This study demonstrates how database studies rooted in benchmarks against previously conducted randomized trials for the drugs of interest can produce complementary evidence to support expanded cardiovascular indications
US$ 25.33
US$ 23.53
US$ 20.25
US$ 29.93
US$ 22.44
US$ 20.67
US$ 23.47
US$ 22.81
US$ 25.20
US$ 26.84
